Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Payables: 2018-2025

  • Dr Reddys Laboratories' Payables rose 64.50% to $862.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.5 billion, marking a year-over-year increase of 9.73%. This contributed to the annual value of $862.0 million for FY2025, which is 64.50% up from last year.
  • As of Q1 2025, Dr Reddys Laboratories' Payables stood at $862.0 million, which was up 64.50% from $524.0 million recorded in Q1 2024.
  • Over the past 5 years, Dr Reddys Laboratories' Payables peaked at $862.0 million during Q1 2025, and registered a low of $412.0 million during Q1 2023.
  • Over the past 3 years, Dr Reddys Laboratories' median Payables value was $524.0 million (recorded in 2024), while the average stood at $599.3 million.
  • Its Payables has fluctuated over the past 5 years, first crashed by 40.63% in 2023, then skyrocketed by 64.50% in 2025.
  • Dr Reddys Laboratories' Payables (Quarterly) stood at $641.0 million in 2021, then increased by 8.27% to $694.0 million in 2022, then crashed by 40.63% to $412.0 million in 2023, then climbed by 27.18% to $524.0 million in 2024, then skyrocketed by 64.50% to $862.0 million in 2025.
  • Its Payables stands at $862.0 million for Q1 2025, versus $524.0 million for Q1 2024 and $412.0 million for Q1 2023.